Nurix Therapeutics, Inc.
NRIXReported to SECin USCIK 0001549595Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 43. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Ring ChristineChief Legal Officer | Option exercise | nothing paid5,787 shares | Sep 2, 2026 | Ring ChristineChief Legal Officer | nothing paid | Option exercise | 5,787 | Sep 2, 2026 |
| Ring ChristineChief Legal Officer | Open-market sell | $10,655400 shares | Sep 2, 2026 | Ring ChristineChief Legal Officer | $10,655 | Open-market sell | 400 | Sep 2, 2026 |
| Ring ChristineChief Legal Officer | Open-market sell | $138,4175,387 shares | Sep 2, 2026 | Ring ChristineChief Legal Officer | $138,417 | Open-market sell | 5,387 | Sep 2, 2026 |
| Ring ChristineChief Legal Officer | Option exercise | $50,4635,787 shares | Sep 2, 2026 | Ring ChristineChief Legal Officer | $50,463 | Option exercise | 5,787 | Sep 2, 2026 |
| Hansen GwennChief Scientific Officer | Option exercise | nothing paid1,452 shares | Sep 1, 2026 | Hansen GwennChief Scientific Officer | nothing paid | Option exercise | 1,452 | Sep 1, 2026 |